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2The FMR1 gene contains a polymorphic CGG trinucleotide sequence within its 5’ 
untranslated region. More than 200 CGG repeats (termed a full mutation) underlie the severe 
neurodevelopmental condition fragile X syndrome, while repeat lengths that range between 
55 and 200 (termed a premutation) result in the conditions fragile X-associated tremor/ataxia 
syndrome (FXTAS) and fragile X-associated premature ovarian insufficiency (FXPOI). 
Premutations in FMR1 are the most common monogenic cause of POI and are routinely 
tested for clinically, however the mechanisms that contribute to the pathology are still largely 
unclear. As studies in this field move towards unravelling the molecular mechanisms 
involved in FXPOI aetiology, we review the evidence surrounding the two main theories 
which describe an RNA toxic gain-of-function mechanism, resulting in the loss of function of 
RNA-binding proteins, or a protein-based mechanism, where repeat-associated non-AUG 
(RAN) translation leads to the formation of an abnormal polyglycine containing protein, 
called FMRpolyG. 
Keywords: FXPOI, molecular mechanisms, RNA gain-of-function, RAN translation
Introduction
Fragile X-associated premature ovarian insufficiency (FXPOI) is among a family of disorders 
caused by the expansion of a CGG trinucleotide repeat sequence located in the 5’ 
untranslated region (UTR) of the FMR1 gene on the X chromosome. This repeat sequence is 
polymorphic in length, with categorisation into four different size ranges (Figure 1). Healthy 
individuals have a normal repeat length with fewer than 44 CGG repeats, while having 
between 45 and 54 repeats is classified as intermediate, or grey zone. Although this sequence 
length is not directly associated with disease phenotypes, some level of CGG repeat 
instability has been reported, which results in variable repeat expansion during mother-
offspring transmission (Nolin et al. , 1996). The range of 55-200 CGG repeats is considered a 
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3premutation, and more than 200 CGG repeats is categorised as a full mutation. Full mutations 
underlie the severe neurodevelopmental condition fragile X syndrome (Kronquist et al. , 
2008), which is the most common cause of inherited intellectual disability and autism in 
males, with patients suffering from a wide range of clinical, cognitive and behavioural 
dysfunctions. While premutation carriers were originally thought to be clinically unaffected, 
it was noted that some females in families with a fragile X male experienced a premature 
menopause, now characterised as FXPOI (Conway et al. , 1998, Cronister et al. , 1991). 
Premutations also result in the more recent described fragile X-associated tremor/ataxia 
syndrome (FXTAS), a multisystem neurological disorder with tremor and ataxia as its 
principal features, which was initially recognised in aging carriers but with clinical features 
potentially also present in children (Hagerman et al. , 2001). Much of the research into the 
molecular mechanisms underlying the pathology of FMR1-associated conditions has focussed 
on the neurological aspects: the aim of this review is to critically appraise putative 
mechanisms underlying the pathogenesis of FXPOI, specifically the evidence investigating 
the RNA gain-of-function hypothesis and the contribution of repeat-associated non-AUG 
(RAN) translation, drawing on parallels in FXTAS and advances made in that disease.
Fragile X-associated POI 
POI is defined as the loss of ovarian hormonal function with evidence of follicle depletion 
before the age of 40 years (Welt, 2008).  It thus has a direct impact on fertility and secondary 
consequences arising from estrogen deficiency, such as osteoporosis and bone fractures 
(Gallagher, 2007), impaired endothelial function (Kalantaridou et al. , 2004), earlier onset of 
coronary heart disease and increased cardiovascular mortality (Mondul et al. , 2005) (see 
Webber et al. , 2016 for a comprehensive review). In addition, women who have a premature 
menopause are reported to suffer from more anxiety, depression and psychological distress 
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4than women with normal ovarian function (Hunter et al. , 2010, van der Stege et al. , 2008). 
Identifiable causes of POI include iatrogenic causes, often secondary to the treatment of 
cancer, and autoimmune causes. Genetic causes remain largely enigmatic, despite the 
identification of a substantial number of genes necessary for normal ovarian function from 
murine knock-out studies (Matzuk, 2000). A clear familial pattern is found in some cases 
even without syndromic conditions such as blepharophimosis/ptosis/epicanthus inversus 
syndrome (BPES) which is associated with mutations in the granulosa cell-specific gene 
FOXL2, (Crisponi et al. , 2001). The X chromosome carries many genes that govern 
follicular maturation and overall ovarian function, and numerical and structural changes in 
this chromosome, as in Turner syndrome or triple X syndrome, are associated with POI 
(reviewed in Fortuño and Labarta, 2014).  Abnormalities in the X-linked FMR1 gene were 
the first causative genetic abnormality identified and are the only monogenic cause currently 
tested for in routine clinical practice, as POI occurs in about 20% of FMR1 premutation 
carriers compared with approximately 1% of all women in the general population (Sherman 
et al. , 2014). CGG repeat length shows a strong non-linear association with penetrance for 
POI (Allen et al. , 2007, Ennis et al. , 2006, Sullivan et al. , 2005, Tejada et al. , 2008). In the 
general population, 29 CGG repeats is the most frequent length observed (Fu et al. , 1991). 
Women carrying midrange repeats (approximately 70-90 repeats) have the highest risk for 
POI, while carriers of smaller and larger premutation repeat lengths have an increased risk of 
POI compared to the general population, but not to the same extent as mid-range carriers. It 
remains contentious whether normal or grey zone CGG repeat lengths are correlated with 
ovarian reserve parameters, age at natural menopause and IVF outcome (Banks et al. , 2016, 
Gleicher et al. , 2011, Gleicher et al. , 2009, Gustin et al. , 2015, Pastore et al. , 2019, 
Voorhuis et al. , 2013).  In addition, X chromosome inactivation (Spath et al. , 2010, Sullivan 
et al., 2005, Tejada et al., 2008), background genes (Hunter et al. , 2008, Spath et al. , 2011) 
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5and smoking (Spath et al., 2011) have all been investigated to explain the incomplete 
penetrance of POI among premutation carriers. 
For many women, the most immediate and significant consequences of POI are amenorrhoea 
and an inability to conceive, however some women present with intermittent ovarian function 
and conceive naturally (Fraison et al. , 2019, Rebar et al. , 1982); thus women with FXPOI 
may have a child with fragile X syndrome due to CGG repeat instability (Nelson et al. , 
2005). Female relatives may also be asymptomatic carriers of expanded repeat number, with 
consequences for themselves and future potential offspring. Although normal-length repeats 
are usually transmitted in a stable manner, the risk of expansion increases with the length of 
the repeat, with grey zone-length repeats expanding to full mutation within several 
generations, and premutations having the highest risk, with expansion to full mutation in one 
generation (Fernandez-Carvajal et al. , 2009, Nolin et al. , 2003). Here, the sex of the 
transmitting parent is important; while the risk of expansion of grey zone alleles is higher for 
fathers than mothers, the expansion of premutation alleles is limited to mothers only (Sullivan 
et al. , 2002). Furthermore, the number and position of AGG nucleotides, which usually 
interrupt the CGG repeat tract (CGG repeats are not ‘pure’) have also been explored.  In their 
absence, the length of pure CGG is increased and is more prone to replication slippage and 
subsequent expansion (Nolin et al. , 2015, Yrigollen et al. , 2012). AGG interruptions have 
also been directly correlated with parameters of the ovarian reserve, with patients having 
longer uninterrupted CGG repeats post-AGG interruptions having the lowest AMH levels and 
antral follicle counts (Lekovich et al. , 2018).  
Clues to the aetiology of FXPOI: physiological and molecular mechanisms
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6The physiological mechanisms that underlie compromised follicular function preceding the 
full development of FXPOI are unclear, but it is proposed these insults could occur at various 
stages of follicular development. These include (i) inadequate formation of the ovarian 
reserve during fetal life and (ii) alterations in follicle recruitment and maturation that cause 
abnormally extensive or fast depletion of the ovarian reserve during post-natal (neonatal, 
childhood and adult) life. While information from women is scarce, the development and use 
of model systems has gone some way towards addressing this, with data available from three 
published knock-in mouse strains, harbouring 130 (here, ‘130R’) (Hoffman et al. , 2012), 90 
(here, ‘90R’) (Lu et al. , 2012) and 100-199 (here, ‘Dutch’) (Bontekoe et al. , 2001) CGG 
repeats in the FMR1 5’UTR, respectively (see (Berman et al. , 2014) and (Sherman et al., 
2014) for comprehensive reviews on these models). There is mostly consensus in the 
reproductive physiology between the 130R and 90R strains, which show that the premutation 
allele does not hinder the establishment of the primordial follicle pool, but rather affects 
ovarian follicle growth and survival, with a parallel decrease in litter size (Pastore and 
Johnson, 2014). Additionally, the growth of ovarian follicles is slower due to an elevation in 
the follicular apoptotic index (Uslu et al. , 2017), with a decrease in the number of cumulus 
granulosa cells associated with mature and ovulatory follicles. Both 130R and 90R models 
are associated with increased levels of follicular atresia and this follicular decline appears to 
affect each follicle stage equally (Hoffman et al., 2012, Lu et al., 2012), in contrast to what is 
seen in many mutant mice with impaired fertility where specific follicle stages are often 
affected. This compromised follicle function was found to correlate with reduced 
mitochondrial DNA copy number, total mitochondrial mass and altered expression of genes 
that control mitochondrial function (Conca Dioguardi et al. , 2016), and while mitochondrial 
abnormalities have been detected in premutation carriers (Alvarez-Mora et al. , 2017), causal 
links between the premutation, mitochondria and follicle function remain to be elucidated. 
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7While granulosa cell abnormalities may be one source of reduced follicle viability, oocytes 
from premutation mice have aberrant localisation of the fragile X mental retardation protein 
(FMRP), with much higher FMRP levels in the nucleus than in the cytoplasm compared with 
wildtype mice (Hoffman et al., 2012). Given that FMRP has been suggested to have a 
function in the nucleus (Bagni and Greenough, 2005), increased expression within the 
nucleus may be deleterious if it causes dysregulation of this function. Furthermore, oocytes of 
premutation mice also have increased ubiquitin levels, which may indicate a reduced 
efficiency of the proteasome system for protein degradation or an increased accumulation of 
abnormal proteins targeted for degradation by ubiquitin (Hoffman et al., 2012). Interestingly, 
an ovarian phenotype has also been observed in the full mutation knockout mouse model, 
with FMR1 knockout mice having an increased number of follicles and larger ovaries than 
wildtype mice, with corpora lutea indicating ovulation (Ascano et al. , 2012). Here the 
authors suggest that loss of FMRP may lead to precocious follicular development, although 
while this model may have the potential to recapitulate ovarian insufficiency through follicle 
over-activation; whether this mechanism is associated with FXPOI is an unanswered 
question. However, women who carry the full mutation do not appear to be at increased risk 
of POI; whether this is because they are heterozygous for the loss of FMRP is unknown 
(Sherman et al., 2014). 
Indeed, and perhaps paradoxically, clues to the aetiology of FXPOI at the molecular level 
may lie in the fact that women carrying full mutations do not develop POI. In FMR1 full 
mutations, the expanded CGG repeat is recognised as a CpG island resulting in methylation, 
chromatin condensation and transcriptional silencing of FMR1 and thus a loss of FMRP 
(Warren, 2007). Two novel regions named FREE1 and FREE2 have also been identified as 
having a role in the epigenetic regulation of FMR1 (Godler et al. , 2010). Largely located 
http://molehr.oxfordjournals.org/
D
ow
nloaded from
 https://academ
ic.oup.com
/m
olehr/advance-article/doi/10.1093/m
olehr/gaaa057/5890487 by U
niversity of Edinburgh user on 02 Septem
ber 2020
8within intron 1, FREE1 and FREE2 are hypermethylated in fragile X individuals but 
unmethylated in carriers of smaller expansions. FMRP is a ribosome-associated RNA-
binding protein that interacts with the coding region of transcripts encoding pre- and post-
synaptic proteins implicated in autism spectrum disorders. FMRP reversibly stalls ribosomes 
on its target mRNAs, and loss of this translational brake on a subset of synaptic proteins 
contributes to fragile X syndrome (Darnell et al. , 2011). Indeed, some authors (Gleicher et 
al., 2009, Schuettler et al. , 2011) speculate that reductions in FMRP expression in granulosa 
cells as a result of the premutation might directly impact the ovarian reserve through 
increased follicle activation, as FMRP may translationally regulate paracrine signals and 
signalling pathways that are important for the regulation of the initiation of follicle growth.  
In particular, data from the ‘90R’ premutation mouse showed reduced expression of 
phosphorylated mTOR (Lu et al., 2012) while the Fmr1 knockout model had elevated mTOR 
levels (Ascano et al., 2012). Dysregulation of mTOR signalling can result in ovarian 
dysfunction, with inhibition of mTOR causing reduced granulosa cell proliferation (Yu et al. , 
2011), which is a notable phenotype in the premutation mouse models. Furthermore, 
experiments in human granulosa cell line COV434 allude to potential interactions between 
AKT/mTOR signalling and FMR1 (Rehnitz et al. , 2017). While significant efforts have been 
made to uncover and validate the mRNA targets of FMRP in the brain (Bagni et al. , 2012, 
Darnell et al. , 2005, Darnell et al., 2011, Maurin et al. , 2018, Suhl et al. , 2014), there has 
been little progress regarding the identification of the direct translational targets of FMRP 
within the ovary. However in premutation and grey zone carriers, FMR1 is transcriptionally 
active and mRNA levels are actually elevated (Tassone et al. , 2007), with reports describing 
a correlation between increasing repeat length, increasing FMR1 transcript levels, and 
decreasing FMRP levels. Thus a key hypothesis is that FMR1 mRNA gain-of-function 
toxicity may underlie FXPOI, as is thought to be the case in the other premutation associated 
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9disorder, FXTAS (Hagerman and Hagerman, 2002)(Figure 2A). An alternative hypothesis 
has also been proposed, based on the observation that repeat sequences can increase the 
frequency at which translation initiates at non-AUG start codons, a process known as repeat-
associated non-AUG (RAN) translation. These false start sites result in polyglycine and/or 
polyalanine-containing proteins that have been shown to be neurotoxic and have been 
detected in the brains of FXTAS patients (Todd et al. , 2013)(Figure 2B). 
RNA gain-of-function toxicity: does it underlie FXPOI?
Several pathologies, such as Huntington’s disease and myotonic dystrophy, are caused by 
trinucleotide expansions, and these expansions can result in either a loss or gain-of-function 
of the translated protein. Fragile X syndrome is an example of where the expansion has a 
loss-of-function mechanism at the protein level, as the trinucleotide repeat results in lower or 
absent levels of the gene product, FMRP (Warren, 2007). When there is a gain-of-function, 
mRNA or protein are thought to acquire a new cellular function depending on the extent and 
localisation of the expansion. In FXTAS, ubiquitin-positive intranuclear inclusions comprised 
of mRNA and protein are observed in the brain (Galloway and Nelson, 2009), and FMR1 
mRNA can be found within these inclusions (Tassone et al. , 2004). This, together with the 
elevated expression of expanded FMR1 mRNA in premutation carriers (Tassone et al. , 
2000a), gave rise to the hypothesis that a toxic mRNA gain-of-function effect might be 
responsible for the development of FXTAS (Greco et al. , 2002, Hagerman et al., 2001, 
Tassone et al., 2000a, Tassone et al. , 2000b). This concept originated from the pathogenesis 
of myotonic dystrophy, where a CUG triplet expansion in the promoter of the DMPK gene 
leads to the formation of intranuclear inclusions. These inclusions sequester the RNA-binding 
protein MBLN, leading to dysregulated splicing of MBLN targets and thus clinical symptoms 
through a deficit of affected proteins (Fardaei et al. , 2001, Kanadia et al. , 2003). If this 
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mechanism does contribute to FXTAS pathogenesis, its involvement in FXPOI may also be 
plausible. 
According to this hypothesised model for FMR1 premutations, expanded CGG-containing 
transcripts are exported from the nucleus in messenger ribonucleoprotein complexes, 
however these transcripts do not join the 40S ribosomal subunit and consequently translation 
is affected, reducing FMRP levels. To compensate, FMR1 transcription is augmented and 
consequently, there is an increase in FMR1 mRNA levels (Oostra and Willemsen, 2003). 
Cells attempt to eliminate surplus FMR1 transcripts via the ubiquitin-proteasome degradation 
pathway (Barasoain et al. , 2016) however when this is not achieved, intranuclear inclusions 
containing CGG-repeat mRNA are formed. Simultaneously, this CGG-repeat mRNA is 
known to adopt secondary structures, such as intramolecular hairpins (Zumwalt et al. , 2007), 
thus RNA-binding proteins could bind to these non-canonical RNA structures, forming RNA-
protein aggregates in cells (Figure 2A). Sequestration of these RNA-binding proteins inhibits 
them from their normal functions, compromising cell integrity and potentially causing cell 
death. It is important to note that in this model, toxicity arises as a result of the expanded 
CGG repeat itself, and not of overexpression of FMR1 protein product, as overexpression of 
FMR1 mRNA without a CGG repeat expansion does not trigger neuronal death or produce 
behavioural deficits (Fernández et al. , 2012). While it was initially suggested that the toxic 
effect of the elevated levels of FMR1 mRNA could lead to a diminished ovarian reserve 
before birth (Conway et al. , 1995), and indeed FMR1 is expressed in germ cells in the human 
fetal ovary (Rosario et al. , 2016), it has since been proposed that ovarian dysfunction 
associated with premutation alleles could be considered a late age-of-onset disease, with 
mRNA toxic effects causing increased atresia of follicles throughout the lifetime (Sullivan et 
al., 2005). Indeed evidence from premutation mouse models is in line with this idea. 
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Comparably, women with type 1 myotonic dystrophy have evidence of a diminished ovarian 
reserve (Srebnik et al. , 2014), thus the accumulation of RNA-protein complexes thought to 
underlie that disease could perhaps also occur in the ovary. 
Alternative mechanisms proposed to describe the toxicity of premutation RNA have 
suggested that expanded-repeat RNA may separately elicit a stress response, evidence of 
which has been observed both in brain tissue of premutation carriers (Chen et al. , 2010) and 
a Drosophila model of repeat RNA toxicity, where the innate immune response is activated 
(Samaraweera et al. , 2013). It is thought that RNA secondary structures may arise in mid-
range CGG repeat carriers with reduced AGG interruptions, which could cause cell 
dysfunction within the ovaries resulting in the diminished ovarian reserve observed in these 
specific carriers (Lekovich et al., 2018). Indeed, hairpin secondary structures formed from 
repeat CGG RNA can act as a substrate for the enzyme Dicer (Handa et al. , 2003), which is 
responsible for generating small RNAs that act via the RNA interference pathway post-
transcriptionally to reduce the expression of complement target genes. While small RNAs 
that are toxic to cultured neuronal cells have been generated from expanded CAG repeats 
(Samaraweera et al., 2013), it remains to be seen whether repeat-CGG RNA can be toxic in 
the same way. Similarly, increased amounts of FMR1 mRNA in granulosa cells could also 
lead to a rise in R-loop formation, a secondary DNA-RNA hybrid structure formed by the 
CGG repeats. The presence of R-loops could lead to increased DNA damage within the cell, 
because in this structure DNA is more unstable and susceptible to mutagenesis and genomic 
instability (Aguilera, 2002, Gan et al. , 2011, Man et al. , 2017). While these structures have 
been observed in cultured human dermal fibroblasts containing the premutation (Loomis et 
al. , 2014), no R-loops have been detected in human granulosa cells. 
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Nevertheless, in support of the FMR1 premutation model and RNA gain-of-function 
hypothesis, increased expression of FMR1 mRNA has been observed in the ovaries of all 
premutation mouse models, with expression being localised to both granulosa cells and 
oocytes (Sherman et al., 2014). Furthermore, although FMRP levels differ among the 
premutation mouse models, likely due to their genetic construction, both the 130R and 90R 
mice have reduced FMRP expression (Sherman et al., 2014). In humans, FMRP is expressed 
in oocytes of fetal ovaries and in granulosa cells of mature follicles (Rife et al. , 2004, 
Rosario et al., 2016), and increased FMR1 transcript levels have been reported in granulosa 
cells of premutation carriers (Elizur et al. , 2014). In that work, the authors also describe a 
significant negative linear correlation between granulosa cell FMR1 expression and the 
number of oocytes retrieved after ovarian stimulation for preimplantation genetic diagnosis, 
with the most obvious effects observed in women carrying mid-range (80-120) repeat 
lengths. While these data are only correlative, these findings suggest that FMR1 mRNA 
accumulation in granulosa cells may be an important cause of follicle dysfunction and loss. A 
preliminary report of in-vitro based studies further demonstrated that transfection of the 
human granulosa cell tumour line COV434 with plasmid DNA expressing 88 CGG repeats 
decreased cell viability after 48 hours (Hubayter et al. , 2009), also supporting a proposed 
toxic RNA gain-of-function mechanism.  
Identification of the proteins that bind and are sequestered by CGG RNA within intranuclear 
inclusions in the brain has been an important step towards understanding the contribution of 
RNA gain-of-function toxicity to the pathogenesis of FXTAS. Several proteins have been 
identified that bind to CGG repeats in FXTAS-affected cells, unlike other disorders 
associated with unstable repeat expansions, which usually have a principle protein deposit 
(Loesch and Hagerman, 2012). RNA binding proteins that have been shown to interact 
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directly with CGG-repeat RNA include hnRNP A2/B1, a protein involved in pre-mRNA 
processing (Jin et al. , 2007, Sellier et al. , 2010), Purα, which is associated with transcription 
regulation in neuronal development (Sellier et al., 2010), and the RNA splicing protein 
MBNL1, a protein also implicated in the pathogenesis of myotonic dystrophy (Loesch and 
Hagerman, 2012). The RNA binding protein DGCR8 has also been demonstrated to bind to 
expanded CGG repeats, resulting in its partial sequestration with its protein partner 
DROSHA, a key enzyme that executes the initiation step of miRNA processing in the nucleus 
(Sellier et al. , 2013). Consequently, miRNA processing was reduced, as evidenced by 
decreased levels of mature miRNAs in neuronal cells expressing CGG repeats and brain 
tissue from FXTAS patients, suggesting that the dysregulation of miRNAs may be involved 
in premutation-related toxicity. Overexpression of hnRNP (Sofola et al. , 2007), Purα (Jin et 
al., 2007) and DROSHA (Sellier et al., 2013) can rescue neurodegeneration in a fly model of 
FXTAS, however whether they can rescue the mammalian phenotype remains to be seen. 
Importantly, CGG RNA aggregates have been shown to be dynamic structures that expand in 
size and number over time (Sellier et al., 2010), thus while some proteins are initially 
sequestered by RNA aggregates in a specific manner, these proteins in turn are able to recruit 
additional proteins.  These include CUGBP1 in the case of hnRNP A2/B1 (Kuyumcu-
Martinez et al. , 2007) and the RNA helicase Rm62 in the case of Purα (Qurashi et al. , 
2011), ultimately causing widespread cellular dysfunction. With regards to relevance for 
FXPOI, the identification of SAM68 in CGG RNA aggregates is particularly meaningful. 
Although the authors used a cell line model of the premutation to demonstrate sequestration 
of SAM68, and consequent loss of its normal alternate splicing function (Sellier et al., 2010), 
SAM68 has been suggested to regulate the mRNA splicing of follicle stimulation hormone 
(FSH) and luteinising hormone (LH) receptors (Bianchi et al. , 2010). Sam68-/- female mice 
are severely subfertile and morphological analyses of the ovary indicated a significant 
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reduction in the number of secondary and pre-antral follicles. 
Crosslinking/immunoprecipitation experiments showed that Sam68 directly binds FSH and 
LH receptor mRNAs, which were downregulated in ovaries of adult knockout mice. Indeed, 
altered splicing of these proteins in FXPOI-affected granulosa cells could lead to FSH and 
LH resistance at the receptor level, preventing follicle maturation (albeit that primordial 
follicle loss rather than gonadotrophin resistance is the ovarian phenotype in FXPOI). 
However, although the proteins discussed here are predicted to be also relevant in the 
pathogenesis of FXPOI, there has been no validation as yet of these proteins in ovary-specific 
premutation models. Furthermore, while a degree of overlap is expected given the parallels 
with FXTAS, it is probable that some deregulated proteins will be specific to granulosa cells, 
thus identification of these ovarian targets will be essential as they are likely to be key in 
understanding the RNA gain-of-function mechanism that may potentially contribute to 
FXPOI. 
Finally, the discovery of long non-coding (lnc) RNAs originating from the FMR1 locus also 
supports RNA toxic gain-of-function as one of the possible pathophysiologic mechanisms 
underlying FXPOI. Using genomic approaches (Khalil et al. , 2008), and more recently, 
‘Deep-RACE’ methodology (Pastori et al. , 2014), the FMR1 gene locus was interrogated for 
the occurrence of novel lncRNAs, leading to the discovery of FMR4, FMR5 and FMR6. 
While FMR5 appeared to show no differential expression between unaffected, premutation 
and full mutation carriers (Pastori et al., 2014), FMR4 was silenced in full mutation carriers 
and upregulated in premutation carriers, similar to FMR1 (Khalil et al., 2008). Unexpectedly 
though, FMR6 was silenced in both full and premutation mutation carriers, suggesting 
abnormal transcription and/or chromatin remodelling prior to transition to the full mutation 
(Khalil et al., 2008). Both FMR4 and FMR6 are thought to regulate FMR1 stability, splicing, 
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subcellular localisation and translational efficiency in FXTAS, and have been proposed to be 
useful biomarkers allowing for early detection and therapeutic intervention in fragile X 
syndrome and FXTAS. FMR6, in particular, may also be useful as a biomarker for FXPOI. In 
a study investigating the relationship between lncRNA accumulation and the pathophysiology 
of FXPOI, there was a non-linear association between the CGG-repeat number and FMR6 
expression in granulosa cells, with the highest levels of FMR6 observed in women with mid-
size CGG repeats (80-120) (Elizur et al. , 2016). In addition, the authors showed that 
increased FMR6 expression had a negative relationship with the number of oocytes retrieved; 
no correlations were observed with FMR4. Thus the production of lncRNAs from the FMR1 
locus may be an additional pathway by which RNA can cause toxicity in FXPOI. 
Repeat-associated non-AUG (RAN) translation: does it contribute to FXPOI?
Translation initiation is highly complex process requiring the step-wise assembly of 
elongation-competent 80S ribosomes at start codons of mRNA. In the canonical ribosome 
scanning model, successful translation of eukaryotic mRNA is thought to require components 
of the preinitiation complex to scan through the 5’UTR in the 5’ to 3’ direction, until it 
encounters an AUG codon in a good Kozak context, at which point, base-pairing between the 
AUG codon and the CAU anti-codon on tRNAMet takes place. The 40S ribosome is now 
committed to its selection of start codon, and is joined by the 60S ribosomal subunit, 
allowing the first peptide bond to be formed, thus beginning translation elongation (see 
(Dever and Green, 2012) for a comprehensive review). In particular, dependency on the RNA 
helicase activity of eIF4A to resolve RNA secondary and tertiary structures is of significance, 
as these structures can impact translation initiation both positively and negatively depending 
on their location (Pestova and Kolupaeva, 2002). Furthermore, these structures can cause 
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multiple atypical modes of initiation, one of which is the translation of mRNA initiated at 
non-AUG start codons. 
RAN translation enables initiation and elongation in the absence of an AUG start codon, 
resulting in the production of multiple homopolymer-containing proteins, depending on the 
reading frame (Green et al. , 2016). Repeat sequences can drive RAN translation whether 
they are located within 5’UTRs, protein-coding reading frames, introns or non-coding RNAs. 
This non-canonical translational initiation process was discovered through the study of CAG 
trinucleotide expansions in the ATXN8 gene, which causes the neurodegenerative disorder 
spinocerebellar ataxia type 8 (SCA8) (Zu et al. , 2011). Unexpectedly, mutation of the only 
AUG codon upstream of the coding sequence did not abolish translation, rather a series of 
homopolymeric proteins were generated with glutamine, serine or alanine repeats. This 
phenomenon was shown to be dependent on the stability of the RNA secondary structures 
formed as a result of the expanded CAG repeats, as decreasing the number of the repeats 
stopped RAN translation. Importantly, polyalanine-ATXN8 proteins have been observed in 
the cerebella of SCA8 human patients and mouse models, and a similar approach has 
provided evidence of a polyglutamine RAN product from the DMPK gene with expanded 
CAG repeats in myotonic dystrophy (Zu et al., 2011). More recently it has been demonstrated 
that the CGG-repeats found in the 5’UTR of FMR1 also support RAN translation initiation, 
thus this may be a potential protein-based mechanism that underlies the development of 
FXTAS and FXPOI (Todd et al., 2013). 
In FXTAS, RAN translation initiated within the 5’UTR can occur in at least two reading 
frames, yielding either a polyglycine product, named FMRpolyG, or a polyalanine product 
(FMRpolyA) (Todd et al., 2013), however it was demonstrated that translation predominantly 
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occurs in the glycine frame through initiation at a near cognate ACG codon located upstream 
of the expanded CGG repeats (Figure 2B) (Sellier et al. , 2017). In accordance with this, 
FMRpolyG protein deposits are found to accumulate in ubiquitin-positive inclusions in the 
brain tissue of humans with FXTAS (Todd et al., 2013); it is unclear at present whether or 
not FMRpolyA is expressed in vivo. Furthermore, it should be noted that RAN translation 
can also occur on non-expanded repeats, thus it may have normal and pathogenic roles (Todd 
et al., 2013). FMRpolyG expression is observed in the ‘Dutch’ premutation mouse, and 
turning off FMR1 transgene expression in this model reverses the formation of neuronal 
FMRpolyG-positive inclusions and FXTAS behavioural deficits (Hukema et al. , 2015). It is 
also proposed that similar to toxic RNA aggregates, FMRpolyG can sequester specific 
proteins required for viable cell function through protein-protein interaction. Indeed, 
FMRpolyG has been shown to interact with LAP2B, a protein essential in anchoring lamina 
proteins to the inner nuclear membrane (Sellier et al., 2017); overexpression of LAP2B 
rescues neuronal cell death induced by the expression of FMRpolyG. Furthermore, 
experiments in Drosophila and premutation cell line models suggest that FMRpolyG 
interferes with the ubiquitin proteasome system, and prevention of RAN translation can 
attenuate this impairment (Oh et al. , 2015). With regards to FXPOI, ubiquitin-positive 
inclusions were frequently observed at a high density within ovarian stromal cell nuclei from 
five women with the condition compared to stromal cells of four control ovaries, where these 
ubiquitin-positive inclusions were much rarer (Chang et al. , 2011). Furthermore, double 
labelling of ubiquitin-positive inclusions found in the stromal cells of one FXPOI patient 
revealed that the vast majority (>90%) of the inclusions also stained positive for FMRpolyG 
(Buijsen et al. , 2016). As the ovarian tissue of this woman with FXPOI did not contain any 
follicles, analyses of the ovaries of the ‘Dutch’ mouse model were undertaken; while the 
ovaries of 20-week old ‘Dutch’ mice contained a few ubiquitin-FMRpolyG-positive 
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inclusions, in 40-week old ‘Dutch’ mice, similar to the FXPOI ovarian tissue, numerous 
intranuclear inclusions were detected in the ovarian stromal cells, both with ubiquitin and 
FMRpolyG antibodies (Buijsen et al., 2016). Interestingly in these studies, oocytes, granulosa 
and theca cells of follicles of all stages were negative for these inclusions, which is surprising 
as these are thought to be the primary cell types affected in FXPOI. It may be the case that 
loss of affected follicles may occur too quickly for the pathological inclusions to be 
visualised, analogous to the situation observed in Purkinje cells of FXTAS patients (Greco et 
al., 2002). In a more recent study however, FMRpolyG aggregates have been identified in 
mural granulosa cells from six FMR1 premutation carriers, and these aggregates showed 
varying levels of co-localisation with ubiquitin (Friedman-Gohas et al. , 2020). None of the 
granulosa cells from the four control women expressed FMRpolyG. Additionally, in-vitro 
work transfecting plasmids expressing premutation-range CGG repeats into COV434 cells 
resulted in the formation of FMRpolyG aggregates (Friedman-Gohas et al., 2020). Therefore, 
while this may provide some evidence that RAN translation and FMRpolyG expression might 
be linked to this premutation disease, significantly more data are necessary to establish 
conclusively whether FMRpolyG-inclusions are a pathological characteristic of FXPOI, and 
of mechanistic importance. 
Concluding remarks
The molecular mechanism underlying FXPOI is enigmatic, and while the study of FXTAS 
and other expanded-repeat disorders has provided some insight, the discovery of RAN 
translation adds an additional complexity as to whether CGG-repeats in the 5’UTR of FMR1 
elicit toxicity via RNA gain-of-function or protein-based means, or a combination of both. 
Transgenic mice expressing both CGG repeat RNA and FMRpolyG protein, but not mice 
expressing only the mutant RNA containing expanded CGG repeats, exhibit inclusion 
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formation and motor phenotypes reminiscent of FXTAS (Sellier et al., 2017), implying that 
RAN protein products play a role in the disease phenotype. However, the ‘130R’ mouse, 
which is unable to make polyglycine and polyalanine proteins due to the position of a stop 
codon in the upstream sequence, still has evidence of ovarian dysfunction, suggesting that at 
least some pathology must arise independently of RAN translation and could be related to the 
elevated levels of premutation FMR1 mRNA. Furthermore, although data from the 
premutation mouse models show there is no detrimental effect on the ovarian reserve at birth, 
it is still a possibility that gonadotoxic RNA or protein aggregates may form during this 
crucial period, with the effects only becoming apparent in post-natal life. However 
establishing the presence of RNA or protein aggregates in follicle structures may be difficult, 
given the limited access to such clinical specimens and the rapid loss of affected follicles in 
POI: only very limited ovarian histological evaluation has been reported in women with 
premutations (Chang et al., 2011). Typical intranuclear inclusion formation has also been 
observed in neurons of the anterior pituitary with degenerative changes in gonadotropic cells 
(Greco et al. , 2007), raising the possibility of abnormal signalling via the hypothalamic-
pituitary-gonadal axis.  However women with FXPOI have the characteristic elevated levels 
of FSH and LH (Murray et al. , 1999) as in other causes of POI, so these inclusions may not 
have any immediate relevance. Finally, it has been shown that FMR1 mRNA in human and 
mouse brain is expressed as a combination of multiple isoforms that use alternative 
transcriptional start sites and different polyadenylation sites, and specific regulation of the 
UTRs is observed in the brains of premutation carriers (Tassone et al. , 2011, Tseng et al. , 
2017). This suggests that transcript variants may play a role in pre-mutation related 
pathologies. Therefore understanding the expression of these different isoforms will be 
fundamental as imbalances in their expression could underlie disease progression.  Thus, 
while using FXTAS as a model to study FXPOI pathogenesis has had some benefit, the 
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central questions which remain unanswered are the relative contributions of RNA gain-of-
function and protein-based pathology to the overall disease phenotype, and the timing and 
location (at the cellular and sub-cellular level) of this insult in the ovary which results in 
follicle atresia and POI. Development of specific cell line and animal models to explore these 
questions will be key in in illuminating the disease biology of FXPOI. 
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Figure legends
Figure 1: CGG repeat length is polymorphic. Normal individuals have fewer than 44 CGG 
repeats (mean 29) and CGG repeat lengths between 45 and 54 are termed grey zone, as they 
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are at risk of developing disease phenotypes due to CGG repeat instability. Individuals with a 
premutation have between 55 and 200 CGG repeats, elevated FMR1 mRNA levels and 
reduced FMRP protein levels, and the premutation causes the conditions fragile X-associated 
premature ovarian insufficiency and fragile X-associated tremor/ataxia syndrome. Individuals 
with more than 200 CGG repeats have a full mutation, where the FMR1 gene is 
transcriptionally silenced, leading to an absence of FMR1 mRNA and FMRP protein. The full 
mutation causes fragile X syndrome. Figure adapted from (Hagerman and Hagerman, 2002).
Figure 2: RNA gain-of-function toxicity and RAN translation-mediated toxicity A: RNA 
gain-of-function toxicity. FMR1 transcription increases to compensate for affected 
translation. Subsequently, premutation CGG repeat lengths form intranuclear aggregates that 
can sequester RNA binding proteins, inhibiting them from carrying out their normal roles, 
leading to cell dysfunction. 2B: Repeat-associated non-AUG (RAN) translation-mediated 
toxicity. Translation of FMR1 mRNA is initiated from a near cognate ACG start codon, 
resulting in the production of polyglycine and/or polyalanine-containing proteins that 
interfere with normal cell function or might be directly toxic. Figure adapted from (Berman et 
al., 2014). 
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 Figure 1: CGG repeat length is polymorphic. Normal individuals have less than 44 CGG repeats (mean 29) 
and CGG repeat lengths between 45 and 54 are termed grey zone, as they are at risk of developing disease 
phenotypes due to CGG repeat instability. Individuals with a premutation have between 55 and 200 CGG 
repeats, elevated FMR1 mRNA levels and reduced FMRP protein levels, and the premutation causes the 
conditions fragile X-associated premature ovarian insufficiency and fragile X-associated tremor/ataxia 
syndrome. Individuals with >200 CGG repeats have a full mutation, where the FMR1 gene is 
transcriptionally silenced, leading to an absence of FMR1 mRNA and FMRP protein. The full mutation causes 
fragile X syndrome. Figure adapted from (Hagerman and Hagerman, 2002). 
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 Figure 2A: RNA gain-of-function toxicity. FMR1 transcription increases to compensate for affected 
translation. Subsequently, premutation CGG repeat lengths form intranuclear aggregates that can sequester 
RNA binding proteins, inhibiting them from carrying out their normal roles, leading to cell dysfunction. 2B: 
Repeat-associated non-AUG (RAN) translation mediated toxicity. Translation of FMR1 mRNA is initiated from 
a near cognate ACG start codon, resulting in the production of polyglycine and/or polyalanine-containing 
proteins that interfere with normal cell function or might directly be toxic. Figure adapted from (Berman et 
al., 2014). 
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